Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$2.83 - $3.94 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024

BUY
$3.06 - $5.58 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024

BUY
$2.03 - $6.59 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024

BUY
$1.4 - $2.09 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023

BUY
$1.6 - $2.78 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023

BUY
$1.6 - $2.78 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023

BUY
$2.46 - $4.07 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023

BUY
$1.38 - $6.0 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023

BUY
$1.14 - $2.0 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022

BUY
$1.88 - $3.03 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022

BUY
$2.02 - $4.53 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022

BUY
$4.04 - $11.43 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022

BUY
$8.39 - $13.64 $0 - $0
0 New
0 $0

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $66.3M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.